Using a 1 M GD-chelate (gadobutrol) for total-body three-dimensional MR angiography: Preliminary experience

Journal of Magnetic Resonance Imaging

Volumn 17, Issue 5, 2003, Pages 565-571

  Goyen, Mathias ^a   Herborn, Christoph U ^a   Vogt, Florian M ^a   Kröger, Knut ^a   Verhagen, Rüdiger ^a   Yang, Fan ^a   Bosk, Silke ^a   Debatin, Jörg F ^a   Ruehm, Stefan G ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Gadobutrol; Gadopentetate dimeglumine; Gd based contrast agents; Magnetic resonance angiography; Whole body MRA

Indexed keywords

GADOBUTROL; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTERY; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIGITAL SUBTRACTION ANGIOGRAPHY; DOSE RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NORMAL HUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SIGNAL NOISE RATIO; THIGH; THREE DIMENSIONAL IMAGING;

ADULT; AGED; AGED, 80 AND OVER; AORTA, THORACIC; ARTERIOSCLEROSIS; CAROTID ARTERIES; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS;

EID: 0037626029     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.10302     Document Type: Article

References (31)

1. Prince MR, Yucel EK, Kaufman JA, Harrison DC, Geller SC. Dynamic gadolinium-enhanced three-dimensional abdominal MR arteriography. J Magn Reson Imaging 1993;3:877-881.
2. Prince MR. Gadolinium-enhanced MR aortography. Radiology 1994;191:155-164.
3. Yucel EK, Anderson CM, Edelman RR, et al. AHA scientific statement. Magnetic resonance angiography: update on applications for extracranial arteries. Circulation 1999;100:2284-2301.
4. Meaney JF, Weg JG, Chenevert TL, Stafford-Johnson D, Hamilton BH, Prince MR. Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med 1997;336:1422-1427.
5. Krinsky GA, Rofsky NM, DeCorato DR, et al. Thoracic aorta: comparison of gadolinium-enhanced three-dimensional MR angiography with conventional MR imaging. Radiology 1997;202:183-193.
6. Prince MR, Narasimham DL, Stanley JC, et al. Breath-hold gadolinium-enhanced MR angiography of the abdominal aorta and its major branches. Radiology 1995; 197:785-792.
7. Prince MR, Schoenberg SO, Ward JS, Londy FJ, Wakefield TW, Stanley JC. Hemodynamically significant atherosclerotic renal artery stenosis: MR angiographic features. Radiology 1997;205:128-136.
8. Shirkhoda A, Konez O, Shetty AN, Bis KG, Ellwood RA, Kirsch MJ. Mesenteric circulation: three-dimensional MR angiography with a gadolinium-enhanced multiecho gradient-echo technique. Radiology 1997;202:257-261.
9. Ho KY, Leiner T, de Haan MW, Kessels AG, Kitslaar PJ, van Engelshoven JM. Peripheral vascular tree stenoses: evaluation with moving-bed infusion-tracking MR angiography. Radiology 1998; 206:683-692.
10. Tello R, Thomson KR, Witte D, Becker GJ, Tress BM. Standard dose Gd-DTPA dynamic MR of renal arteries. J Magn Reson Imaging 1998:8:421-426.
11. Hany TF, Debatin JF, Leung DA. Pfammatter T. Evaluation of the aortoiliac and renal arteries: comparison of breath-hold, contrast-enhanced, three-dimensional MR angiography with conventional catheter angiography. Radiology 1997;204:357-362.
12. Nelson KL. Gifford LM. Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology 1995;196: 439-443.
13. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996;6:162-166.
14. Staks T, Schuhmann-Giampieri G, Frenzel T. Weinmann HJ, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29:709-715.
15. Benner T. Reimer P. Erb G, et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 2000; 12:371-380.
16. Goyen M, Lauenstein TC, Herbom CU, Debatin JF. Bosk S, Ruehm SG. 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose -independent effect on image quality of pelvic three-dimensional MR-angiography. J Magn Reson Imaging 2001;14: 602-607.
17. Ruehm SG. Goyen M. Barkhausen J, et al. Rapid magnetic resonance angiography for detection of atherosclerosis. Lancet 2001;357:1086-1091.
18. Goyen M, Quick HH, Debatin JF, et al. Whole body 3D MR angiography using a rolling table platform: initial clinical experience. Radiology 2002:224:270-277.
19. Ruehm SG, Goyen M, Quick HH, et al. Whole-body MRA on a rolling table platform (AngioSURF). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2000;172:670-674.
20. Goyen M, Herbom CU, Lauenstein TC, Debatin JF, Bosk S, Ruehm SG. Optimization of contrast dosage for gadobenate dimeglumine- enhanced high-resolution whole body 3D MR angiography. Invest Radiol 2002;37:263-268.
21. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
22. Lauffer RB, Parmelee DJ, Ouellet HS, et al. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996;3(Suppl 2):356-358.
23. Knopp MV, von Tengg-Kobligk H, Floemer F, Schoenberg SO. Contrast agents for MRA: future directions. J Magn Reson Imaging 1999;10:314-316.
24. Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 2002;12:1550-1556.
25. Lemke AJ, Sander B, Balzer T, Geens V. Hosten N, Felix R. Safety and use of gadobutrol in patients with brain tumors (phase III trial). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997;167: 591-598.
26. Tombach B, Bremer C, Reimer P.et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000;35:35-40.
27. Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001;218:651-657.
28. Tombach B, Bremer C, Reimer P, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol 2002; 178:105-109.
29. Mühler A, Weinmann HJ. Arterial concentrations following intravenous bolus injection of gadobutrol. Comparison of 0.5 and 1.0 M stock solutions. In: Proceedings of the 3rd Annual Meeting of ISMRM, Nice, France, 1995. p 1128.
30. Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrast-enhanced three-dimensional MR angiography with conventional digital subtraction angiography. AJR Am J Roentgenol 2000,174:171-179.
31. Ruehm SG, Hany TF, Pfammatter T. Schneider E, Ladd M, Debatin JF. Pelvic and lower extremity arterial imaging: diagnostic performance of three-dimensional contrast-enhanced MR angiography. AJR Am J Roentgenol 2000;174:1127-1135.